Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 21% ± 5% |
Insufficient scRNA-seq data for expression of EID2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 522.14 | 180 / 180 | 100% | 35.27 | 430 / 430 |
uterus | 100% | 626.86 | 170 / 170 | 100% | 43.62 | 459 / 459 |
esophagus | 100% | 684.35 | 1444 / 1445 | 100% | 23.73 | 183 / 183 |
brain | 100% | 1122.17 | 2640 / 2642 | 100% | 43.00 | 705 / 705 |
intestine | 100% | 640.99 | 966 / 966 | 100% | 23.96 | 526 / 527 |
kidney | 100% | 596.35 | 89 / 89 | 100% | 23.93 | 899 / 901 |
stomach | 100% | 519.68 | 358 / 359 | 100% | 23.77 | 286 / 286 |
thymus | 100% | 662.44 | 652 / 653 | 100% | 38.29 | 604 / 605 |
prostate | 100% | 585.74 | 245 / 245 | 100% | 39.37 | 500 / 502 |
adrenal gland | 100% | 1254.41 | 258 / 258 | 100% | 46.23 | 229 / 230 |
breast | 100% | 618.93 | 459 / 459 | 100% | 34.92 | 1113 / 1118 |
liver | 100% | 388.44 | 226 / 226 | 100% | 19.94 | 404 / 406 |
bladder | 100% | 571.24 | 21 / 21 | 99% | 31.09 | 501 / 504 |
skin | 100% | 630.65 | 1809 / 1809 | 99% | 31.35 | 469 / 472 |
lung | 99% | 601.67 | 574 / 578 | 100% | 32.27 | 1155 / 1155 |
pancreas | 97% | 317.35 | 319 / 328 | 100% | 30.30 | 178 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 28.39 | 29 / 29 |
spleen | 100% | 688.30 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 30.19 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 36.36 | 1 / 1 |
adipose | 100% | 639.37 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 558.16 | 1331 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 465.80 | 800 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 438.90 | 837 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 18.44 | 76 / 80 |
peripheral blood | 64% | 209.65 | 591 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060392 | Biological process | negative regulation of SMAD protein signal transduction |
GO_0030154 | Biological process | cell differentiation |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0007181 | Biological process | transforming growth factor beta receptor complex assembly |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0007517 | Biological process | muscle organ development |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0005515 | Molecular function | protein binding |
GO_0046332 | Molecular function | SMAD binding |
Gene name | EID2 |
Protein name | EP300-interacting inhibitor of differentiation 2 (EID-2) (CREBBP/EP300 inhibitor 2) (EID-1-like inhibitor of differentiation 2) EID2 protein |
Synonyms | CRI2 |
Description | FUNCTION: Interacts with EP300 and acts as a repressor of MYOD-dependent transcription and muscle differentiation. Inhibits EP300 histone acetyltransferase activity. Acts as a repressor of TGFB/SMAD transcriptional responses. May act as a repressor of the TGFB/SMAD3-dependent signaling by selectively blocking formation of TGFB-induced SMAD3-SMAD4 complex. . |
Accessions | Q6IPM4 ENST00000390658.4 [Q8N6I1-1] Q8N6I1 |